Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
ISSN Print: 2278-1668, Online: 2278-0513
ARTICLE
Year: 2016   |   Volume: 5   |   Issue: 2   |   Page: 178-180     View issue

Leucine replaced by methionine at 273 position in chronic myeloid leukemia: Knowns and unknowns…


, , ,
Abstract

Chronic myeloid leukemia is a clonal bone marrow stem cell disorder characterized by the presence of Philadelphia chromosome t(9;22)(q34;q11) leading to fusion oncogene BCR-ABL. Tyrosine kinase inhibitors (TKIs) act by competitively inhibiting BCR-ABL oncoprotein with significant response rates. However, up to 30% of patients fail to achieve complete cytogenetic remission on 1st line TKI imatinib, one of the reasons being mutations in BCR-ABL kinase domain leading to imatinib resistance. Over 80 such mutations have been documented in the literature; however, some of the rare mutations still remain to be studied for their impact in development of resistance and their responsiveness to currently available therapeutic options. Here, we report one such case of a rare mutation leucine replaced by methionine at 273 position and its clinical implications.

Cite this article
Vancouver
Thanky A, Kanakasetty G, Mallekavu S, Kuntejowdahalli L. Leucine replaced by methionine at 273 position in chronic myeloid leukemia: Knowns and unknowns…. Clin Cancer Investig J. 2016;5(2):178-80. https://doi.org/10.4103/2278-0513.177135
APA
Thanky, A., Kanakasetty, G., Mallekavu, S., & Kuntejowdahalli, L. (2016). Leucine replaced by methionine at 273 position in chronic myeloid leukemia: Knowns and unknowns…. Clinical Cancer Investigation Journal, 5(2), 178-180. https://doi.org/10.4103/2278-0513.177135

© Clinical Cancer Investigation Journal
Online since 01 December, 2011
Creative Commons License 
ISSN Print: 2278-1668, Online: 2278-0513